The U.S. Food and Drug Administration has approved Ixempra (ixabepilone), a new anti-cancer treatment, for use in patients with metastatic or locally advanced breast cancer who have not responded to certain other cancer drugs. The FDA evaluated Ixempra under priority review, completing its assessment of the drug's safety and effectiveness in six months. Breast Cancer Treatment: FDA Approves Ixempra for Advanced Breast Cancer Patients
Monday, October 22, 2007
Subscribe to:
Post Comments (Atom)
Posts
No comments:
Post a Comment